Our Programs
Our pipeline includes four clinical-stage drug candidates targeting different mechanisms critical to overcoming cancer progression and drug resistance:
- Pracinostat, an oral HDAC inhibitor;
- ME-401, an oral PI3K delta inhibitor;
- Voruciclib, an oral CDK inhibitor; and
- ME-344, a mitochondrial inhibitor targeting the OXPHOS complex.
Our portfolio is built around drug candidates with validated targets and is designed to develop medicines that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other medicines.
HDAC Inhibitor
DRUG CANDIDATE
Pracinostat HDAC Inhibitor
INDICATION / COMBINATION
Acute Myeloid Leukemia
Unfit for intensive chemotherapy
Vidaza® (azacitidine)
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal
INDICATION / COMBINATION
Myelodysplastic Syndrome
High & very high risk
Vidaza® (azacitidine)
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal
PI3K Delta Inhibitor
DRUG CANDIDATE
ME-401 PI3K Delta Inhibitor
INDICATION / COMBINATION
Follicular Lymphoma
Relapsed/refractory
Single agent
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal
INDICATION / COMBINATION
B-Cell Malignancies
Relapsed/refractory
Single-agent
• Rituxan® (rituximab)
• Zanubrutinib‡
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal
Selective CDK Inhibitor
DRUG CANDIDATE
Voruciclib CDK Inhibitor
INDICATION / COMBINATION
B-Cell Malignancies
Relapsed/refractory
Single agent
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal
Mitochondrial Inhibitor
DRUG CANDIDATE
ME-344 Mitochondrial Inhibitor
INDICATION / COMBINATION
HER2-Breast Cancer§
Treatment-naïve, early stage
Avastin® (bevacizumab)
Pre-Clinical
Clinical Proof-Of-Concept
Pivotal
† Phase 2 study intended to support an accelerated approval marketing application with the FDA
‡ Study arm to be initiated under clinical collaboration with Beigene, Ltd.
§ Investigator-initiated study
